Stock listing
EX9 Stock Price, News, Filings & Events — Exelixis, Inc.
Selected listing: EX9 · GETTEX · EUR · DE
This page tracks Exelixis, Inc.'s EX9:GETTEX listing on GETTEX in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following EX9:GETTEX. EX9:GETTEX is the stock-level entry point for investors researching Exelixis, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
- Ticker
- EX9:GETTEX
- Asset type
- Stock
- Market cap
- $14.47B
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- GETTEX
- Currency
- EUR
Exelixis, Inc. EX9:GETTEX stock context
This page tracks Exelixis, Inc.'s EX9:GETTEX listing on GETTEX in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following EX9:GETTEX. EX9:GETTEX is the stock-level entry point for investors researching Exelixis, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
Latest news from Exelixis, Inc.
Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories
August 31, 2026
Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update
August 5, 2026
Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026
July 22, 2026
Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
June 21, 2026
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
May 29, 2026
Exelixis, Inc. earnings calls
Exelixis, Inc. (EXEL) Q2 2026 Earnings Call
August 5, 2026 · Replay with transcript and chapters
Exelixis, Inc. (EXEL) Q1 2026 Earnings Call
May 5, 2026 · Replay with transcript and chapters
Exelixis, Inc. (EXEL) Q4 2025 Earnings Call
February 10, 2026 · Replay with transcript and chapters
Exelixis, Inc. (EXEL) Q3 2025 Earnings Call
November 4, 2025 · Replay with transcript and chapters
Exelixis, Inc. (EXEL) Q2 2025 Earnings Call
July 28, 2025 · Replay with transcript and chapters
Exelixis, Inc. (EXEL) Q1 2025 Earnings Call
May 13, 2025 · Replay with transcript and chapters
Research Exelixis, Inc.
Alternate listings
EXEL:NASDAQ
US · USD
Alternate listing for Exelixis, Inc.; the primary context on this page is EX9:GETTEX.
936718:LSX
DE · EUR
Alternate listing for Exelixis, Inc.; the primary context on this page is EX9:GETTEX.
EX9:TRADEGATE
DE · EUR
Alternate listing for Exelixis, Inc.; the primary context on this page is EX9:GETTEX.
936718:LS
DE · EUR
Alternate listing for Exelixis, Inc.; the primary context on this page is EX9:GETTEX.
0IJO:LSE
GB · USD
Alternate listing for Exelixis, Inc.; the primary context on this page is EX9:GETTEX.
EX9:FWB
DE · EUR
Alternate listing for Exelixis, Inc.; the primary context on this page is EX9:GETTEX.
1EXEL:MIL
IT · EUR
Alternate listing for Exelixis, Inc.; the primary context on this page is EX9:GETTEX.
E2XE34:BMFBOVESPA
BR · BRL
Alternate listing for Exelixis, Inc.; the primary context on this page is EX9:GETTEX.
EXEL:BOATS
US · USD
Alternate listing for Exelixis, Inc.; the primary context on this page is EX9:GETTEX.
EX9:SWB
DE · EUR
Alternate listing for Exelixis, Inc.; the primary context on this page is EX9:GETTEX.
EX9:BX
CH · CHF
Alternate listing for Exelixis, Inc.; the primary context on this page is EX9:GETTEX.
EX9:DUS
DE · EUR
Alternate listing for Exelixis, Inc.; the primary context on this page is EX9:GETTEX.